Dr. Thomas Rinderknecht 47 Dr. Rinderknecht joined the Board of Directors in January 2001 and serves on its Compensation Committee.He also served on the Audit Committee until March 14, 2002.He has also been a director of Permatec since its founding in June 1997.Dr. Rinderknecht has been a partner in the firm of Rinderknecht Klein & Stadelhofer in Zurich, Switzerland since 1985, and has been practicing commercial law in Europe since 1982.He holds law degrees from the University of Zurich, Switzerland and the University of Munich, Germany.
...The Audit Committee
, consisting of Mr. Evenstad, Dr. Philippe Dro and Dr. Thomas Rinderknecht
met three times during 2001.
...The Compensation Committee
, consisting of Mr. Clark, Dr. Gonella and Dr. Rinderknecht
, met informally during 2001 with compensation actions being considered by the full Board.
No member of the Compensation Committee was, during the 2001 fiscal year or previously, an officer or employee of ANTARES PHARMA INC
, nor did any member have any relationship or transaction with ANTARES PHARMA INC
which is required to be reported under Item 402(k) of Regulation S-K under the Securities Exchange Act of 1934, as amended, except for Dr. Rinderknecht
.Dr. Rinderknecht served as a member of both the Audit Committee and the Compensation Committee and his law firm, Rinderknecht, Klein & Stadelhofer, of which he is a principle, also served as legal advisor on various matters.ANTARES PHARMA INC
recognized expenses of $97,292 for services provided by Rinderknecht, Klein & Stadelhofer
in 2001. Section 16(a) Beneficial Ownership Reporting Compliance Section 16 (a) of the Securities Exchange Act of 1934 requires the Company's directors, certain officers and persons who own more than ten percent of a registered class of ANTARES PHARMA INC's
equity securities, to file reports of ownership on Form 3 and changes in ownership on Forms 4 or 5 with the SEC
.Such officers, directors and ten percent shareholders are also required by the SEC's rules to furnish ANTARES PHARMA INC
with copies of all Section 16(a) reports they file. Specific due dates for such reports have been established by the SEC
and ANTARES PHARMA INC
is required to disclose any failure to file reports by such dates.Based solely on a review of the copies of such reports received by ANTARES PHARMA INC
or by written representations from certain reporting persons, ANTARES PHARMA INC
believes that during the year ended December 31, 2001, all Section 16(a) filing requirements applicable to officers, directors and ten percent shareholders were met.